Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/1750743X.2025.2457931 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Highlights from the breakout session: optimising new treatments.
Rheumatology (Oxford)
March 2025
Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
This session presented emerging realworld evidence on novel glucocorticoid (GC) sparing therapies for ANCA-associated vasculitis (AAV). It covered the first-in-class oral C5a receptor antagonist avacopan for severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and antiinterleukin-5 therapies in the management of eosinophilic granulomatosis with polyangiitis (EGPA). Avacopan was approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of AAV in 2021, following the phase 3 ADVOCAT E trial comparing oral avacopan to an oral GC taper for GPA and MPA.
View Article and Find Full Text PDFNatural killer cells in the lung: novel insight and future challenge in the airway diseases.
ERJ Open Res
March 2025
Respiratory Diseases Unit, Department of Medical Sciences, Surgery and Neurosciences, Siena University Hospital, Siena, Italy.
Natural killer (NK) cells are innate lymphoid cells which are present in the lung as circulating and resident cells. They are key players both in airway surveillance and in crosstalk with (COPD) pathogenesis, and they seem to contribute to the development of bronchiectasis. In asthma, NK cell dysfunction was observed mainly in severe forms, and it can lead to a biased type-2 immune response and failure in the resolution of eosinophilic inflammation that characterise both allergic and eosinophilic phenotypes.
View Article and Find Full Text PDFSuccessful treatment by switching from benralizumab to dupilumab in a patient with allergic bronchopulmonary mycosis caused by Schizophyllumcommune.
Respir Investig
March 2025
Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, 143-8541, Japan.
A 79-year-old female patient with a history of bronchial asthma was diagnosed with allergic bronchopulmonary aspergillosis. Her symptoms temporarily improved with inhaled corticosteroid/long-acting β2-agonist therapy. However, 10 months after treatment, her asthma symptoms worsened.
View Article and Find Full Text PDFEffectiveness of biological therapy in severe asthma: a retrospective real-world study.
Croat Med J
February 2025
Marina Lampalo, Clinical Department for Lung Diseases Jordanovac, University Hospital Center Zagreb, Jordanovac 104, 10000 Zagreb, Croatia,
Unlabelled: Aim- To compare the effectiveness of different biologic medications for the treatment of severe asthma.
Methods: We retrospectively collected data on 74 patients treated with one of four different biologics (omalizumab, mepolizumab, reslizumab, or benralizumab) at the Jordanovac Clinic for Pulmonary Diseases, Zagreb, Croatia for at least two years. The patients were compared in terms of the number of exacerbations, dose of oral corticosteroids (OCS), asthma control test (ACT), forced expiratory volume in 1 second (FEV1), forced vital capacity, fraction of exhaled nitric oxide (FeNO), number of blood eosinophils, and total immunoglobulin E (IgE).
Biologic Therapies for Severe Asthma in School-Age Children.
Respir Care
March 2025
Dr. Bacharier is affiliated with Department of Pediatrics, Monroe Carrel Jr Children's Hospital at Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Children with severe asthma incur substantial disease-related morbidity. Despite treatment with inhaled corticosteroids and additional controller medications, many patients continue to experience recurrent exacerbations, impaired lung function, and diminished quality of life. Most children with severe asthma demonstrate evidence of a phenotype consistent with ongoing type 2 inflammation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!